Qiagen N.V. (ETR:QIA)
36.61
-0.20 (-0.53%)
Mar 31, 2025, 2:45 PM CET
Qiagen Revenue
In the year 2024, Qiagen had annual revenue of $1.98B USD with 0.66% growth. Qiagen had revenue of $521.20M in the quarter ending December 31, 2024, with 2.36% growth.
Revenue
$1.98B
Revenue Growth
+0.66%
P/S Ratio
n/a
Revenue / Employee
$347.06K
Employees
5,700
Market Cap
7.95B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 22.67B |
Merck KGaA | 21.16B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Qiagen News
- 25 days ago - Qiagen NV (QGEN) Secures FDA Clearance for New Gastrointestinal Panel - GuruFocus
- 25 days ago - QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Wallstreet:Online
- 25 days ago - QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Business Wire
- 4 weeks ago - QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - Wallstreet:Online
- 4 weeks ago - QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - Business Wire
- 4 weeks ago - Qiagen N.V.: Some Clarity Needed Before Buying The Dip - Seeking Alpha
- 5 weeks ago - Qiagen, Bio-Techne downgraded at Baird amid NIH funding concerns - Seeking Alpha
- 6 weeks ago - QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region - Business Wire